The trial, Javelin DLBCL, NCT02951156, evaluated Avelumab, an anti-PD-L1 agent and Utomilumab, a fully human IgG2 CD 137/4-1BB agonist in different combinations with Rituximab, Azacitidine, and Bendamustine, versus the investigator’s choice of Rituximab and Bendamustine or Rituximab, Gemcitabine, and Oxaliplatin. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.